Nicolas Girard, MD

Videos

PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

10/23/2023

Nicolas Girard , MD;

Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.

Prof Nicolas Girard, MD,...

10/23/2023

Oncology

Videos

Adding Relatlimab to First-Line Nivolumab and Chemotherapy Demonstrates Clinical Benefit in Advanced Non-Small Cell Lung Cancer

09/14/2024

Nicolas Girard , MD;

Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...

Nicolas Girard, MD, PhD,...

09/14/2024

Oncology